GENE ONLINE|News &
Opinion
Blog

2021-10-14| In-Depth

Anti-cancer Agent Derived From Himalayan Caterpillar Fungus Shines in Early Trials

by Manju Bhaskar
Share To
Cancer continues to be one of the deadliest diseases on the planet. According to the International Agency for Research on Cancer, in 2018, there were 18.1 million new diagnoses around the world, and about 9.5 million reported deaths.

Last week, NuCana, a UK-based clinical-stage biopharma, announced promising results in an early clinical trial for its potent anti-cancer molecule NUC-7738 derived from Himalayan Caterpillar Fungus.

NUC-7738 is synthesized by researchers at the University of Oxford in partnership with NuCana. Researchers reported encouraging signals of anti-tumor activity and prolonged disease stabilization in patients participating in the ongoing Phase 1 trial, which began in 2019.

NuCana harnesses the power of ProTide technology (phosphoramidate chemistry) to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs. Hugh S. Griffith, Founder and CEO of believes “NuCana is striving to significantly improve outcomes for patients by transforming chemotherapy and pioneering a new era in oncology.”

GO Prime with only $1.49 now

LATEST
University of Pittsburgh Study Finds Flu Vaccines Prevent Up to 41.5 Percent of Infections in Simulated Communities
2025-07-19
Pharmacist-Led Initiatives Boost Pneumococcal Vaccine Uptake Among Older Adults Through Education and Direct Immunization Services
2025-07-19
Study Finds Agricultural Dust Exposure Alters Gut Microbiota and Weakens Intestinal Barrier in Mice
2025-07-19
Biotech Leaders Urge FDA to Reject Conservative Report Criticizing Mifepristone Safety Profile
2025-07-19
Physician Calls for Better Diagnosis of Cannabinoid Hyperemesis Syndrome Amid Discussions on Drug Pricing and Accessibility
2025-07-19
Maternal Vaccination Linked to Reduced RSV Hospitalizations in Newborns
2025-07-18
FDA Advisory Committee Votes Against Approval of GSK’s Blenrep Ahead of PDUFA Date
2025-07-18
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top